公开(公告)号：US20250002601A1

公开(公告)日：2025-01-02

申请号：US18568806

申请日：2022-06-08

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  YANNIS MOREL ,  OLIVIER DEMARIA ,  BENJAMIN ROSSI

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/55

Abstract: The present invention relates to multispecific protein that binds to human NKp46, human CD20, human CD122, and optionally human CD16A. The protein according to the invention have utility in the treatment of disease, such as cancer.

公开(公告)号：US20200325232A1

公开(公告)日：2020-10-15

申请号：US16765486

申请日：2018-11-19

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/68

Abstract: Multimeric multispecific proteins that bind multiple target antigens are provided. The proteins have particular advantages when configured to bind a NK or T cell activating receptor and one or two cancer associated antigens, and can be used in the treatment of disease, notably cancer.

公开(公告)号：US20190276536A1

公开(公告)日：2019-09-12

申请号：US16398472

申请日：2019-04-30

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  NICOLAS SCHNEIDER

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/26 ,  C07K16/30 ,  A61K47/02 ,  A61K47/12

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US20190225703A1

公开(公告)日：2019-07-25

申请号：US15767661

申请日：2016-10-11

Applicant: INNATE PHARMA ,  CENTRE LEON BERARD

Inventor： CHRISTOPHE CAUX ,  LAURENT GAUTHIER ,  NICOLAS GOURDIN ,  CHRISTINE MENETRIER-CAUX ,  CARINE PATUREL ,  IVAN PERROT

IPC: C07K16/28 ,  C07K16/40 ,  A61P35/00

Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.

公开(公告)号：US20180237536A1

公开(公告)日：2018-08-23

申请号：US15517991

申请日：2015-10-09

Applicant: INNATE PHARMA

Inventor： IVAN PERROT ,  CARINE PATUREL ,  LAURENT GAUTHIER

IPC: C07K16/28

Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US20160046713A1

公开(公告)日：2016-02-18

申请号：US14924786

申请日：2015-10-28

Applicant: INNATE PHARMA

Inventor： NICOLAS ANFOSSI ,  LAURENT GAUTHIER ,  YANNIS MOREL ,  ALESSANDRO MORETTA ,  SILVIA PAROLINI ,  BENJAMIN ROSSI

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.

Abstract translation: 本发明提供能够结合KIR3D多肽的抗原结合蛋白。 抗体在治疗特征为表达KIR3DL2的细胞，特别是CD4 + T细胞，包括恶性肿瘤例如真菌病真菌和Sézary综合征的疾病中具有增加的活性。

公开(公告)号：US20220340661A1

公开(公告)日：2022-10-27

申请号：US17852419

申请日：2022-06-29

Applicant: INNATE PHARMA

Inventor： NADIA ANCERIZ ,  MATHIEU BLERY ,  LAURENT GAUTHIER ,  CARINE PATUREL

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/569

Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

公开(公告)号：US20200369765A1

公开(公告)日：2020-11-26

申请号：US16629588

申请日：2018-07-09

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN ,  LAURENT GAUTHIER

IPC: C07K16/28

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US20190322767A1

公开(公告)日：2019-10-24

申请号：US16472233

申请日：2017-12-21

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: Provided are heterodimeric proteins formed from dimerization between CH1 and CK domains and that bind a target antigen on a cell to be depleted. The proteins have advantages in production and in the treatment of disease, notably solid tumors or infectious disease.

公开(公告)号：US20180030144A1

公开(公告)日：2018-02-01

申请号：US15551919

申请日：2016-02-19

Applicant: INNATE PHARMA

Inventor： STEPHANIE CHANTEUX ,  CARINE PATUREL ,  IVAN PERROT ,  LAURENT GAUTHIER

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2896 ,  C07K16/40 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12Y301/03005

Abstract: This invention relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.